文献速递胸部肿瘤

恶性胸膜间皮瘤中错配修复蛋白缺陷与微卫星不稳定性分析

Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma.
PubMed 文献 · J Thorac Oncol · 2018-07-26

该研究对335例恶性胸膜间皮瘤患者组织芯片进行四种错配修复蛋白免疫组化检测,发现329例蛋白完整,6例蛋白缺失者经MSI分析均为阴性,未发现MSI患者,提示抗PD-1免疫治疗获益可能由其他机制驱动。

要点

  • 335例恶性胸膜间皮瘤中,329例错配修复蛋白免疫组化完整。
  • 6例错配修复蛋白缺失样本经MSI分析均确认为阴性。
  • 未发现微卫星不稳定性患者,抗PD-1疗效可能由其他机制驱动。

核心结论

  • 在该大型回顾性系列中,未发现恶性胸膜间皮瘤患者存在微卫星不稳定性。
  • 抗PD-1免疫治疗的应答可能由其他机制驱动。

研究设计与样本

  • 使用包含335例恶性胸膜间皮瘤患者的组织芯片进行回顾性分析。
  • 对四种常见错配修复蛋白(MLH1、PMS2、MSH2、MSH6)进行免疫组化检测。
  • 对免疫组化结果不确定的样本分离DNA,采用Promega MSI Analysis System(版本1.2)分析微卫星不稳定性。

主要发现

  • 335例患者中,329例免疫组化显示错配修复蛋白完整。
  • 6例免疫组化提示错配修复蛋白缺失的样本经MSI分析均确认为阴性。
  • 6例免疫组化阴性样本中,5例PD-L1染色阴性,1例染色超过5%。

临床怎么用

  • 恶性胸膜间皮瘤中MSI罕见,常规MSI检测可能无法筛选抗PD-1治疗获益人群。

局限性

  • 回顾性研究设计。
  • 样本来源于组织芯片,可能存在取材局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Malignant pleural mesothelioma is an aggressive malignancy with limited systemic therapy options. Promising results have been reported with use of anti-programmed cell death 1 therapy; however, its benefits appear to be confined to a subgroup of patients. Microsatellite instability (MSI) results from the inactivation of DNA mismatch repair genes and results in a high tumor mutational burden, a phenomenon that has not been seen with mesothelioma. MSI and protein absence have been shown to correlate in colorectal cancer, such that most centers have adopted immunohistochemistry (IHC) to screen for MSI-high colorectal cancers. We profiled a large cohort of patients with mesothelioma to determine the rate of negative IHC staining results the four common mismatch repair proteins. DESIGN: A tissue microarray comprising 335 patients with malignant pleural mesothelioma were used. IHC for the four common mismatch repair proteins (mutL homolog 1; PMS1 homolog 2, mismatch repair system component; mutS homolog 2; and mutS homolog 6) was performed. Programmed death ligand 1 IHC staining with the E1L3N clone was also performed. DNA was isolated from IHC equivocal samples and analyzed for microsatellite instability by using the Promega MSI Analysis System (version 1.2, Promega, Madison, WI). RESULTS: Of the patients profiled, 329 had intact mismatch repair proteins by IHC. Six samples with IHC testing results indicating absent mismatch repair protein were analyzed for MSI and confirmed to be negative. Of the six IHC-negative samples, five were negative for programmed death ligand 1 staining and one sample had more than 5% staining. CONCLUSION: In this large retrospective series, we were unable to identify any patients with malignant pleural mesothelioma with microsatellite instability. Response to anti-programmed cell death 1-based immunotherapy may be driven by other mechanisms.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Arulananda S, Thapa B, Walkiewicz M, et al. Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma. J Thorac Oncol. 2018. PMID: 30056163. doi:10.1016/j.jtho.2018.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。